Related references
Note: Only part of the references are listed.Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to the age of 60 years with Philadelphia chromosome-negative acute lymphoblastic leukemia
Mark B. Geyer et al.
HAEMATOLOGICA (2021)
A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 PatientsKey terms
Prashant R. Tembhare et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2020)
At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial
Chezi Ganzel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
Franco Locatelli et al.
BLOOD CANCER JOURNAL (2020)
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study
Hagop M. Kantarjian et al.
CANCER (2019)
A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia
Renato Bassan et al.
HAEMATOLOGICA (2019)
Automated Flow Cytometric MRD Assessment in Childhood Acute B- Lymphoblastic Leukemia Using Supervised Machine Learning
Michael Reiter et al.
CYTOMETRY PART A (2019)
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
Kevin J. Curran et al.
BLOOD (2019)
A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy
Sindhu Cherian et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2018)
Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia
Aijie Huang et al.
LEUKEMIA & LYMPHOMA (2018)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
Katherine C. Pehlivan et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2018)
Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome
Bor-Sheng Ko et al.
EBIOMEDICINE (2018)
Universal monitoring of minimal residual disease in acute myeloid leukemia
Elaine Coustan-Smith et al.
JCI INSIGHT (2018)
Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL
Brent Wood et al.
BLOOD (2018)
Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia
Prisca Theunissen et al.
BLOOD (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation
Monika Brueggemann et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Rebecca A. Gardner et al.
BLOOD (2017)
Principles of Minimal Residual Disease Detection for Hematopoietic Neoplasms by Flow Cytometry
Brent L. Wood
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Hoelzer et al.
ANNALS OF ONCOLOGY (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
B-ALL Minimal Residual Disease Flow Cytometry An Application of a Novel Method for Optimization of a Single-Tube Model
Aaron C. Shaver et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2015)
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232
Michael J. Borowitz et al.
BLOOD (2015)
Detection of minimal residual disease in B lymphoblastic leukemia using viSNE
Joseph A. DiGiuseppe et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2015)
Personalized medicine in adult acute lymphoblastic leukemia
Dieter Hoelzer
HAEMATOLOGICA (2015)
Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia
Leonid Karawajew et al.
HAEMATOLOGICA (2015)
Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment
C. Eckert et al.
LEUKEMIA (2015)
Personalized medicine in adult acute lymphoblastic leukemia
Dieter Hoelzer
HAEMATOLOGICA (2015)
Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia
Leonid Karawajew et al.
HAEMATOLOGICA (2015)
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia
Kheira Beldjord et al.
BLOOD (2014)
Validation of Cell-based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS - Part V - Assay Performance Criteria
Brent Wood et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2013)
Relapsed childhood acute lymphoblastic leukaemia
Deepa Bhojwani et al.
LANCET ONCOLOGY (2013)
Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL
R. Garand et al.
LEUKEMIA (2013)
Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia
B. Denys et al.
LEUKEMIA (2013)
Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007
Graca M. Dores et al.
BLOOD (2012)
Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia
Giuseppe Gaipa et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Basophils and plasmacytoid dendritic cells are potential sources for error in flow cytometric monitoring of patients receiving anti-CD22 therapies. AKA not all anti-CD22 antibodies are created equal
Malcolm Acon-Laws et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
New markers for minimal residual disease detection in acute lymphoblastic leukemia
Elaine Coustan-Smith et al.
BLOOD (2011)
Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry
Ingrid Thorn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia
Patricia Stow et al.
BLOOD (2010)
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
Renato Bassan et al.
BLOOD (2009)
Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches
Jacqueline Ryan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
CD22 Expression on Blastic Plasmacytoid Dendritic Cell Neoplasms and Reactivity of Anti-CD22 Antibodies to Peripheral Blood Dendritic Cells
Edmunds Z. Reineks et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2009)
Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group
Peter Bader et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
Michael J. Borowitz et al.
BLOOD (2008)
Analysis of minimal residual disease in childhood acute lymphoblastic leukemia:: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping
M Malec et al.
LEUKEMIA (2004)
Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia
GAM Neale et al.
LEUKEMIA (2004)
Share Paper
